| Name | Apratastat |
|---|---|
| Synonyms |
(3S)-N-Hydroxy-4-({4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl}sulfonyl)-2,2-dimethyl-3-thiomorpholinecarboxamide
TMI 005 (3S)-N-hydroxy-4-({4-[(4-hydroxybut-2-yn-1-yl)oxy]phenyl}sulfonyl)-2,2-dimethylthiomorpholine-3-carboxamide MFCD13152357 3-Thiomorpholinecarboxamide, N-hydroxy-4-[[4-[(4-hydroxy-2-butyn-1-yl)oxy]phenyl]sulfonyl]-2,2-dimethyl-, (3S)- Apratastat |
| Description | Apratastat is an orally active, potent, and reversible dual inhibitor of tumor necrosis factor-α converting enzyme (TACE) and matrix metalloproteinases (MMPs) . Apratastat can potently inhibit the release of TNF-α in vitro, ex vivo, and in vivo with IC50s of 144 ng/mL in vitro and 81.7 ng/mL ex vivo, respectively[1]. |
|---|---|
| Related Catalog | |
| Target |
TNF-α MMP |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Molecular Formula | C17H22N2O6S2 |
| Molecular Weight | 414.496 |
| Exact Mass | 414.091919 |
| LogP | 1.42 |
| Index of Refraction | 1.607 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P301 + P312 + P330 |
| Hazard Codes | Xi |
| RIDADR | NONH for all modes of transport |